Amarin Corp Plc (AMRN)

[Number sleven]

Golden, For the same reason that nobody had any interest until after R-IT results were published. People don't do research. JELIS should have made the R-IT outcome predictable. The same situation is in play now. There is no cost effective alternative to Icosapent ethyl in conjunction with Statin therapy. At least nothing that has a similar RRR. People believe that the US market is gone and there is no way for Amarin to become profitable in Europe. Most investors don't know anything about that companies they own beyond the closing share price. We live in a world where people can't grasp an idea that doesn't fit on a bumper sticker.
That is why.
Sleven,